U.S. Stock Night Market Movements
BGM fell 11.85% in the night market. Based on recent news:
<ol>
<li>
On March 23, Dr. Craig Tendler, former global head of oncology clinical development at Johnson &amp; Johnson, joined TuHURA Biosciences to lead its VISTA project. This news raised concerns about management changes at Johnson &amp; Johnson, leading to a decline in stock price.
</li>
<li>
On March 22, MarketBeat reported that Johnson &amp; Johnson was not included in the list of five stocks recommended by top analysts. Analysts rated Johnson &amp; Johnson as &#34;moderate buy,&#34; but believed there were better investment options, which weakened market confidence.
</li>
<li>
On March 21, MarketBeat reiterated that Johnson &amp; Johnson was not listed as one of the best investment choices by top analysts, further undermining investor confidence. The market is sensitive to management changes and analyst ratings at Johnson &amp; Johnson. Competition in the pharmaceutical industry is intensifying, and market segmentation is evident.
</li>
</ol>
Stocks with High Trading Volume in the Industry
Eli Lilly fell 0.02% in the night market. Based on recent news:
<ol>
<li>
On March 24, Innovent Biologics and Eli Lilly's strategic cooperation agreement officially took effect. Innovent Biologics will receive a $350 million upfront payment and is eligible for up to $8.85 billion in milestone payments. This collaboration aids Eli Lilly's global R&amp;D in oncology and immunology, boosting market confidence.
</li>
<li>
On March 23, Minister of Commerce Wang Wentao met with Eli Lilly's Chairman and CEO David Ricks to discuss U.S.-China economic and trade relations and Eli Lilly's business in China. Eli Lilly plans to invest an additional $3 billion in China over the next decade to support the &#34;Healthy China&#34; initiative, demonstrating long-term confidence in the Chinese market.
</li>
<li>
On March 24, Eli Lilly announced that its weight loss drug significantly reduced blood sugar levels in clinical trials, with participants averaging a weight loss of 36.6 pounds. This result raised market expectations for Eli Lilly's weight loss drug, driving stock price fluctuations. The pharmaceutical industry outlook is generally positive, with clear policy support.
</li>
</ol>
Novo Nordisk rose 0.52% in the night market. Based on recent news:
<ol>
<li>
On March 23, Novo Nordisk announced a meeting with the Vice Minister of Commerce of China to discuss its operations and future development plans in China. This move shows the company's emphasis on the Chinese market, enhancing investor confidence and driving stock price up.
</li>
<li>
On March 23, Novo Nordisk announced the launch of a DKK 15 billion stock repurchase program. This move was interpreted by the market as a sign of the company's confidence in future development, further boosting stock prices.
</li>
<li>
On March 23, Novo Nordisk's patent for semaglutide in the Chinese market expired, and it is expected to face competition from generic drugs. Nevertheless, the company is actively positioning itself in the market to maintain a competitive advantage. Competition in the pharmaceutical industry is intensifying, and market segmentation is evident.
</li>
</ol>
Terns rose 4.67%. Based on recent key news:
<ol>
<li>On March 25, Merck announced the acquisition of Terns Pharmaceuticals at $53 per share, with a total transaction value of approximately $6.7 billion. This news drove Terns' stock price up by 5.3%
Source: Financial Associated Press</li>
</ol>
On March 25, Terns' core drug TERN-701 demonstrated a 75% major molecular response rate in clinical trials, and analysts believe it has the potential to become a competitor to Novartis' drug Scemblix. Source: Zhitong Finance
On March 25, Merck's acquisition plan is seen as a move to strengthen its oncology drug development pipeline ahead of the patent expiration of its blockbuster drug Keytruda. Source: Jiemian News The pharmaceutical industry is active in mergers and acquisitions, with a focus on policy changes

BGM fell 11.85% in the night session; Eli Lilly fell 0.02% in the night session, with a transaction volume of USD 53,100; Novo Nordisk rose 0.52% in the night session, with a transaction volume of USD 49,600; Terns Pharmaceuticals rose 4.67% in the night session, with a transaction volume of USD 34,500

Price Alert

U.S. stock night trading volatility: Johnson & Johnson fell 11.85% in after-hours trading, with management changes and analyst ratings delivering a double blow to market confidence